Presentation Archives - Page 3 of 9

Evaluation of Bispecific Antibodies in NHPs

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen...

BTK Inhibitor-Resistant Lymphoma Animal Models

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use...

Oncogenic Virus-associated Tumor Models

Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily...

Fibroblast Growth Factor Receptors

Fibroblast growth factor receptor (FGFR) signaling pathways represent promising targets for therapeutics owing to their role in development, tissue, and...

ErbB Receptor Tyrosine Kinase Platform

The ErbB family of receptor tyrosine kinases are involved in key cellular functions, including cell growth and survival. ErbB family...

Phosphatidylinositol Kinases: Structural Biology Services

Within the phosphatidylinositol 3-kinase (PI3K) family, the heterodimer comprising the p110-α catalytic and p85-α regulatory subunits (encoded by PIK3CA and...

Janus Kinases: Structural Biology Services

The inhibition of the JAK/STAT signaling pathway is a promising approach for the treatment of cancers and inflammatory diseases. To...

CRBN Structural Biology Services

Targeted protein degradation of disease-causing proteins by the E3 ligase cereblon (CRBN) represents a new therapeutic strategy for addressing challenging-to-treat...

WRN Helicase: Structural Biology Services

Inhibition of the Werner syndrome RecQ helicase (WRN) is a promising approach for the treatment of cancers commonly associated with...

Knowledge Library